Teduglutide is used to treat short bowel syndrome in adults who depend on intravenous (parenteral) feeding to receive nutrition.
Gattex is a drug made in Israel, United States. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Teduglutide is a complete analogue of Gattex. It has the same composition, dosage and methods of use. Also Teduglutide has a lower cost compared to Gattex.
To buy Gattex, click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
Side effects
Tell your doctor about any unusual or bothersome side effect. cough changes in appetite dilated neck veins inability to speak loss of consciousness Indigestion swelling of the abdominal or stomach area tightness in the chest
Warnings
Teduglutide is not approved for use by anyone younger than 18 years old.
Interactions
Benzodiazepines: Teduglutide may increase the serum concentration of Benzodiazepines. Monitor therapy
Food interaction
Pregnancy
- If you are or think you could be pregnant, you should get medical advice from your doctor before taking this medicine.
- If used during pregnancy large amounts or use for long periods of time should be avoided.
- The safety and effectiveness of this medication have not been established for pregnant women.
Overview
Non – Guideline-Supported Use
There is limited information regarding Off-Label Example – Guideline-Supported Use of Teduglutide in pediatric patients.
Contraindications
Warnings
Precautions
- Acceleration of Neoplastic Growth
- Based on the pharmacologic activity and findings in animals, GATTEX has the potential to cause hyperplastic changes including neoplasia. In patients at increased risk for malignancy, the clinical decision to use GATTEX should be considered only if the benefits outweigh the Gattex. In patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic), GATTEX therapy should be discontinued. In patients with active non-gastrointestinal malignancy, the clinical decision to continue GATTEX should be made based on risk-benefit considerations.
- Colorectal polyps were identified during the clinical trials. Colonoscopy of the entire colon with removal of polyps should be done within 6 months prior to starting treatment with GATTEX. A follow-up colonoscopy (or alternate imaging) is recommended at the end of 1 year of GATTEX. Subsequent colonoscopies should be done every 5 years or more often as needed. If a polyp is found, adherence to current polyp follow-up guidelines is recommended. In case of diagnosis of colorectal cancer, GATTEX therapy Gattex be discontinued.
- Based on benign tumor findings in the rat carcinogenicity study, patients should be monitored clinically for small bowel neoplasia. If a benign neoplasm is found, it should be removed. In case of small bowel cancer, GATTEX therapy should be discontinued.
- Intestinal obstruction has been reported in clinical trials. In patients who develop intestinal or stomal obstruction, GATTEX should be temporarily discontinued while the patient is clinically managed. GATTEX may be restarted when the obstructive presentation resolves, if clinically indicated.
- Biliary and Pancreatic Disease
- Gallbladder and Biliary Tract Disease
- Cholecystitis, cholangitis, and cholelithiasis, have been reported in clinical studies. For identification of the onset or worsening of gallbladder / biliary disease, patients should undergo laboratory assessment of bilirubin and alkaline phosphatase within 6 months prior to starting GATTEX, and at least every 6 months while on GATTEX; or more frequently if needed. If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder and / or biliary tract is recommended; and the need for continued GATTEX treatment should be reassessed.
- Pancreatitis has been reported in clinical studies. For best way of onset or worsening of pancreatic disease, patients should undergo laboratory assessment of lipase and amylase within 6 months prior to starting GATTEX, and at least every 6 months while on GATTEX; or more frequently if needed. If clinically meaningful changes are seen, further evaluation such as imaging of the pancreas is recommended; and the need for continued GATTEX treatment should be reassessed.
- Fluid overload and congestive heart failure have been observed in clinical trials, which were felt to be related to enhanced fluid absorption associated with GATTEX. If fluid overload occurs, parenteral support should be adjusted and GATTEX treatment should be reassessed, especially in patients with underlying cardiovascular disease. If significant cardiac deterioration develops while on GATTEX, the need for continued GATTEX treatment should be reassessed.
- Increased Absorption of Concomitant Oral Medication
- Altered mental status in association with GATTEX has been observed in patients on benzodiazepines in clinical trials. Patients on concomitant oral drugs (e.g., benzodiazepines, phenothiazines) requiring titration or with a narrow therapeutic index may require dose adjustment while on GATTEX.
Reverse reactions
Clinical Trials Experience
- Because clinical trials are conducted under w>
- In placebo-controlled Studies 1 and 3, 12% of patients in each of the placebo and GATTEX study groups experienced an injection site reaction.
Adverse reactions of special interest
- Malignancy. Three subjects were diagnosed with malignancy in the clinical studies, all of whom were male and had received GATTEX 0.05 mg / kg / day in Study 2. One subject had a history of abdominal radiation for Hodgkin's disease two decades prior to receiving GATTEX and prior liver lesion on CT scan, and was diagnosed with metastatic adenocarcinoma of unconfirmed origin after 11 months of exposure to GATTEX. Two subjects had extensive smoking histories, and were diagnosed with lung cancers (squamous and non-small cell) after 12 months and 3 months of GATTEX exposure, respectively.
